Andere Sprachen IR-Med Inc.

Aktien

A2QMUF

US46265R1032

IRME

Markt geschlossen - OTC Markets Andere Börsenplätze 18:08:30 26.04.2024			% 5 Tage	% 1. Jan.
0.9 ^USD	-5.26%		-5.26%	-21.74%

05.04.	PressureSafe von IR-Med Inc. erhält FDA-Listung für die Indikation der Entscheidungshilfe bei Druckverletzungen	CI
01.04.	IR-Med Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	05.04.
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	05.04.
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
IR-Med Inc. and I.R Med Ltd. Appoints Aharon Klein as Interim Chief Executive Officer	05.03.
IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer	28.02.
IR-Med Inc. Announces Resignation of Inna Martin as Director	23.02.
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries	20.02.
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16	13.02.
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe? Device at NPIAP 2024 Annual Conference on February 16	13.02.
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine	21.12.
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue	07.12.
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer	04.10.23
IR-MED Announces Executive Changes Effective as of October 15, 2023	04.10.23
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024	26.09.23
Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024	26.09.23
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board	13.09.23
IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board	13.09.23
IR-MED Chairman & Interim CEO Issues Letter to Shareholders	21.08.23
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen IR-Med Inc.

Aktien

A2QMUF

US46265R1032

IRME

Andere Sprachen

Filter